ReviewCancers2023
Current Status and Future Prospects for Esophageal Cancer.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
169 citing papers in PubMed, 1 synthesis or guideline pooled it, 232 citations in OpenAlex.
- Prognostic and clinicopathological impact of systemic inflammation response index (SIRI) on patients with esophageal cancer: a meta-analysis.Systematic reviews · 2025Pooled it
- Effects of low-dose esketamine on early quality of recovery following minimally invasive esophagectomy: a multicenter, randomized controlled study.Annals of medicine · 2026Trial
- Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial.Molecular cancer · 2025Trial
- Single-cell and machine learning identify a trihydroxybutyrylation-related prognostic signature in esophageal cancer.Journal of thoracic disease · 2026Article
- Temporal Transcriptomic Profiling of NMBA-Induced Rat Esophageal Squamous Carcinogenesis Identifies Early Inflammatory Activation and Late NRF2-Associated Oxidative-Stress Remodeling.International journal of molecular sciences · 2026Article
- Socioeconomic Disparities in the Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus to Esophageal Adenocarcinoma.Annals of surgery · 2026Article
- Article
- Integrative Analysis of IGFL2‑AS1 and BRCA1 Expression in Esophageal Cancer: An Experimental and Bioinformatics‑Based Study.Iranian biomedical journal · 2026Article
- DDR1 in esophageal squamous cell carcinoma: bioinformatics discovery and experimental validation.Translational cancer research · 2026Article
- Article
- ASAP3 activates the NF-κB signaling pathway to promote the progression of esophageal squamous cell carcinoma.Discover oncology · 2026Article
- Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers.Molecular cancer therapeutics · 2026Article
- Targeting APE1-Redox Function Reverses SOX9-mediated Chemoresistance in Esophageal Adenocarcinoma.Gastroenterology · 2026Article
- Repurposing melatonin for its potential roles in gastrointestinal cancers: highlighting the molecular mechanisms.Cancer cell international · 2026Review
- Identification of replication factor C subunit 4 as a potential therapeutic target in esophageal squamous cell carcinoma based on bioinformatic analysis and machine learning.Discover oncology · 2026Article
- Lactylome Reprogramming Mediates Therapeutic Response and Adaptation to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.Molecular & cellular proteomics : MCP · 2026Article
- Identification and validation of prognostic genes related to mitochondrial dynamics and mitochondrial autophagy in esophageal squamous cell carcinoma.Journal of thoracic disease · 2026Article
- miR-3678-3p Promotes Esophageal Squamous Cell Carcinoma Progression by Regulating Phosphatase and Tensin Homolog.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Targeting the ROS-JNK/p38 Axis: Schisandrin A as a Novel Therapeutic Candidate for Esophageal Squamous Cell Carcinoma.Journal of microbiology and biotechnology · 2026Article
- A ferroptosis-related competing endogenous RNA network: HOX transcript antisense intergenic RNA/miR-129-5p/brain and acute leukemia, cytoplasmic axis contributes to the malignant progression of esophageal squamous cell carcinoma.Translational cancer research · 2026Article
109 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Esophageal cancer (EC) is the ninth most common cancer and the sixth leading cause of cancer deaths worldwide. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two main histological subtypes with distinct epidemiological and clinical features. While the global incidence of ESCC is declining, the incidence of EAC is increasing in many countries. Decades of epidemiologic research have identified distinct environmental exposures for ESCC and EAC subtypes. Recent advances in understanding the genomic aspects of EC have advanced our understanding of EC causes and led to using specific genomic alterations in EC tumors as biomarkers for early diagnosis, treatment, and prognosis of this cancer. Nevertheless, the prognosis of EC is still poor, with a five-year survival rate of less than 20%. Currently, there are significant challenges for early detection and secondary prevention for both ESCC and EAC subtypes, but Cytosponge™ is shifting this position for EAC. Primary prevention remains the preferred strategy for reducing the global burden of EC. In this review, we will summarize recent advances, current status, and future prospects of the studies related to epidemiology, time trends, environmental risk factors, prevention, early diagnosis, and treatment for both EC subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.